Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31266701 | 1.00 | KDM4E (0.45) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL25568535 | 0.82 | KDM4E (0.43) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL24423147 | 0.81 | SLC6A2 (0.43) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL25090905 | 0.81 | SLC6A2 (0.43) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL383264 | 0.81 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL24678312 | 0.81 | KDM4E (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL383265 | 0.81 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL20576050 | 0.81 | KDM4E (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL2144199 | 0.81 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL1543272 | 0.81 | SLC6A2 (0.42) | KDM4EATMNPSR1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514858-B2 | CD38 inhibitors | Astellas Engineered Small Molecules US, Incorporated (US) | 2026-01-06 | — | — | US | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4132919-A1 | CD38 INHIBITORS | Mitobridge, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KDM4E 391/4885ATM 759/4885NPSR1 4287/4885 |
| US-20230158024-A1 | CD38 INHIBITORS | CD38, NQO1, NDUFAB1 | KDM4E 1196/4885ATM 3709/4885NPSR1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.